AbCellera Biologics Inc. ABCL Licensing and royalty revenue — Settlement receivable
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by AbCellera Biologics Inc. in its filing.
Tagged under the XBRL concept abcl:RevenueFromContractWithCustomerExcludingAssessedTaxSettlementReceivable.
The official record: AbCellera Biologics Inc.’s 10-K, filed February 24, 2026, on SEC EDGAR. View the filing →
Ask your AI about AbCellera Biologics Inc.'s licensing and royalty revenue — settlement receivable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is AbCellera Biologics Inc.'s licensing and royalty revenue — settlement receivable?
- AbCellera Biologics Inc. (ABCL) reported licensing and royalty revenue — settlement receivable of $9M in Q4 2025.
- What does licensing and royalty revenue — settlement receivable mean?
- This metric tracks the outstanding financial obligations owed to the company resulting from legal or contractual settlements related to licensing agreements. It represents a claim for future cash inflows that have been recognized as revenue but not yet collected. Monitoring this balance is essential for assessing the company's liquidity position and the collectability of non-recurring, high-value contractual windfalls.